21sme.com

Reuters - U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol medicine Vytorin after a study showed it was no better than a generic drug in preventing the build-up of fatty plaque.

Alwaleed to boost Citigroup stake to 5 percent (Reuters)

Stock futures extend losses on jobless claims (Reuters)

Global job losses rise as recession plays on (Reuters)

Children's Place profit up (Reuters)

GMAC applies for bank status (Reuters)

PepsiCo stands by 2008 earnings outlook (Reuters)

SKorean stocks fall sharply after Wall Street drop (AP)

The Bank Terrorist (Investor's Business Daily)

U.S. prices drop at record pace, China wary of unrest (Reuters)

Lower Wall St. open seen on auto bailout woe (Reuters)

October consumer prices and home starts plummet (Reuters)

Toyota to cut output and Nissan downbeat (Reuters)

SolarWorld in shock Opel offer (Reuters)

BASF issues profit warning, cuts global output (Reuters)

Japan banks, U.S. carmakers seek funds (Reuters)

Woolworths plunges on news it may sell stores (AP)

Stock futures sink ahead of data; autos eyed (Reuters)

FTSE 100 dips 0.12% (AFP)

Toyota to cut output, Nissan downbeat (Reuters)

Asian stocks slip as auto crisis deepens (AFP)